BR112017016084A2 - composição e método para o tratamento da doença veno-oclusiva hepática - Google Patents

composição e método para o tratamento da doença veno-oclusiva hepática

Info

Publication number
BR112017016084A2
BR112017016084A2 BR112017016084A BR112017016084A BR112017016084A2 BR 112017016084 A2 BR112017016084 A2 BR 112017016084A2 BR 112017016084 A BR112017016084 A BR 112017016084A BR 112017016084 A BR112017016084 A BR 112017016084A BR 112017016084 A2 BR112017016084 A2 BR 112017016084A2
Authority
BR
Brazil
Prior art keywords
treatment
composition
occlusive disease
hepatic veno
veno
Prior art date
Application number
BR112017016084A
Other languages
English (en)
Inventor
Michael Freissmuth
Zahra Kazemi
Ursula Lemberger
Madeleine Themanns
Eva-Maria Zebedin-Brandl
Christoph Österreicher
Original Assignee
Scipharm Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sarl filed Critical Scipharm Sarl
Publication of BR112017016084A2 publication Critical patent/BR112017016084A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

?composição e método para o tratamento da doença veno-oclusiva hepática?. a presente invenção se refere a uma composição compreendendo um análogo, um derivado ou um sal farmaceuticamente aceitável de prostaciclina para utilização na prevenção ou no tratamento de síndrome da obstrução sinusoidal e/ou doença veno-oclusiva hepática (dvo).
BR112017016084A 2015-01-27 2016-01-27 composição e método para o tratamento da doença veno-oclusiva hepática BR112017016084A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152665 2015-01-27
PCT/EP2016/051675 WO2016120311A1 (en) 2015-01-27 2016-01-27 Composition for the treatment of hepatic veno-occlusive disease

Publications (1)

Publication Number Publication Date
BR112017016084A2 true BR112017016084A2 (pt) 2018-03-27

Family

ID=52394992

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016084A BR112017016084A2 (pt) 2015-01-27 2016-01-27 composição e método para o tratamento da doença veno-oclusiva hepática

Country Status (14)

Country Link
US (1) US20180021347A1 (pt)
EP (1) EP3250289A1 (pt)
JP (1) JP2018503654A (pt)
KR (1) KR20170106360A (pt)
CN (1) CN107592811A (pt)
AU (1) AU2016212091A1 (pt)
BR (1) BR112017016084A2 (pt)
CA (1) CA2973147A1 (pt)
CL (1) CL2017001904A1 (pt)
EA (1) EA201791696A1 (pt)
IL (1) IL253390A0 (pt)
SG (1) SG11201705809QA (pt)
WO (1) WO2016120311A1 (pt)
ZA (1) ZA201704957B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764505C (en) 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2943479B1 (en) 2013-01-11 2020-04-15 Corsair Pharma, Inc. Prodrugs of treprostinil
ES2754388T3 (es) 2013-03-15 2020-04-17 Mannkind Corp Composiciones y métodos de dicetopiperazina microcristalina
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
AU2020211412A1 (en) * 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments

Also Published As

Publication number Publication date
EA201791696A1 (ru) 2017-11-30
US20180021347A1 (en) 2018-01-25
IL253390A0 (en) 2017-09-28
AU2016212091A1 (en) 2017-08-03
KR20170106360A (ko) 2017-09-20
WO2016120311A1 (en) 2016-08-04
CL2017001904A1 (es) 2018-03-23
CA2973147A1 (en) 2016-08-04
EP3250289A1 (en) 2017-12-06
SG11201705809QA (en) 2017-08-30
CN107592811A (zh) 2018-01-16
JP2018503654A (ja) 2018-02-08
ZA201704957B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
SV2018005643A (es) Composiciones de insulina de rapida accion
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
GT201400111A (es) Triazolopiridinas sustituidas
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
DOP2016000253A (es) Nuevos compuestos
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
WO2015001541A3 (en) Pharmaceutical film composition
BR112018069900A2 (pt) composição antimicrobiana, método de limpeza ou desinfecção de uma superfície e uso de um complexo fosfolipídico catiônico
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
MX2018013203A (es) Ciclodextrinas como procoagulantes.
BR112018007651A2 (pt) composição de limpeza antimicrobiana, método para a desinfecção de uma superfície e utilização de uma composição
BR112018007374A2 (pt) composição farmacêutica
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
BR112018004249A2 (pt) composto, e, composição para prevenção ou tratamento de doenças trombóticas.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]